Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

New, potent, selective, and short-acting peptidic V1a receptor agonists.

Wisniewski K, Galyean R, Tariga H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewska H, Laporte R, Rivière PJ, Schteingart CD.

J Med Chem. 2011 Jul 14;54(13):4388-98. doi: 10.1021/jm200278m. Epub 2011 Jun 20.

PMID:
21688787
[PubMed - indexed for MEDLINE]
2.

Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.

Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.

J Pharmacol Exp Ther. 2011 Jun;337(3):786-96. doi: 10.1124/jpet.111.178848. Epub 2011 Mar 16.

PMID:
21411496
[PubMed - indexed for MEDLINE]
Free Article
3.

Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.

J Med Chem. 2004 Apr 22;47(9):2375-88.

PMID:
15084136
[PubMed - indexed for MEDLINE]
4.

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.

J Med Chem. 2007 Feb 22;50(4):835-47.

PMID:
17300166
[PubMed - indexed for MEDLINE]
5.

An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.

Manning M, Cheng LL, Stoev S, Bankowski K, Przybyiski J, Klis WA, Sawyer WH, Wo NC, Chan WY.

J Pept Sci. 1995 Jan-Feb;1(1):66-79.

PMID:
9222985
[PubMed - indexed for MEDLINE]
6.

Design and synthesis of potent, highly selective vasopressin hypotensive agonists.

Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH.

J Pept Sci. 2006 Sep;12(9):592-604.

PMID:
16625682
[PubMed - indexed for MEDLINE]
7.

Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.

Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.

J Pept Sci. 2006 Mar;12(3):190-8.

PMID:
16130178
[PubMed - indexed for MEDLINE]
8.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.

Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Review.

PMID:
18655903
[PubMed - indexed for MEDLINE]
9.

A new series of photoactivatable and iodinatable linear vasopressin antagonists.

Carnazzi E, Aumelas A, Barberis C, Guillon G, Seyer R.

J Med Chem. 1994 Jun 10;37(12):1841-9.

PMID:
8021923
[PubMed - indexed for MEDLINE]
10.

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T.

J Med Chem. 2002 Jun 6;45(12):2579-88.

PMID:
12036367
[PubMed - indexed for MEDLINE]
11.

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.

Rehberg S, Enkhbaatar P, Rehberg J, La E, Ferdyan N, Qi S, Wisniewski K, Traber LD, Schteingart CD, Rivière PJ, Laporte R, Traber DL.

Crit Care Med. 2012 Jun;40(6):1957-60. doi: 10.1097/CCM.0b013e31824e0fe5.

PMID:
22488005
[PubMed - indexed for MEDLINE]
12.

Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors.

Chan WY, Wo NC, Stoev S, Cheng LL, Manning M.

Br J Pharmacol. 1998 Oct;125(4):803-11.

PMID:
9831918
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Role of V1a receptor in AVP-induced restoration of vascular hyporeactivity and its relationship to MLCP-MLC20 phosphorylation pathway.

Yang G, Xu J, Li T, Ming J, Chen W, Liu L.

J Surg Res. 2010 Jun 15;161(2):312-20. doi: 10.1016/j.jss.2009.01.005. Epub 2009 Jan 27.

PMID:
19577256
[PubMed - indexed for MEDLINE]
14.

Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.

Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.

Eur J Pharmacol. 2008 Aug 20;590(1-3):333-42. doi: 10.1016/j.ejphar.2008.06.010. Epub 2008 Jun 7.

PMID:
18599033
[PubMed - indexed for MEDLINE]
15.

Brain vasopressin and sodium appetite.

Flynn FW, Kirchner TR, Clinton ME.

Am J Physiol Regul Integr Comp Physiol. 2002 Apr;282(4):R1236-44.

PMID:
11893630
[PubMed - indexed for MEDLINE]
16.

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

Manning M, Stoev S, Kolodziejczyk A, Klis WA, Kruszynski M, Misicka A, Olma A, Wo NC, Sawyer WH.

J Med Chem. 1990 Nov;33(11):3079-86.

PMID:
2231609
[PubMed - indexed for MEDLINE]
17.

Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus.

Hawtin SR, Wesley VJ, Parslow RA, Patel S, Wheatley M.

Biochemistry. 2000 Nov 7;39(44):13524-33.

PMID:
11063589
[PubMed - indexed for MEDLINE]
18.

Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis.

Rehberg S, Yamamoto Y, Sousse L, Bartha E, Jonkam C, Hasselbach AK, Traber LD, Cox RA, Westphal M, Enkhbaatar P, Traber DL.

Am J Physiol Heart Circ Physiol. 2012 Nov 15;303(10):H1245-54. doi: 10.1152/ajpheart.00390.2012. Epub 2012 Sep 7.

PMID:
22961865
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.

Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G.

Endocrinology. 2007 Sep;148(9):4136-46. Epub 2007 May 10.

PMID:
17495006
[PubMed - indexed for MEDLINE]
20.

Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats.

Bucher M, Hobbhahn J, Taeger K, Kurtz A.

Am J Physiol Regul Integr Comp Physiol. 2002 Apr;282(4):R979-84.

PMID:
11893600
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk